Atty. Dkt. No.
037003-0280062Client Ref.
2000-30-0178A

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Applicant: HANNA et al.

Appln. No.: 09/822,672

Filing Date: April 02, 2001

Date: June 1, 2004

Page 1 of 1

Examiner: Larry R. Helms

Group Art Unit: 1642

U.S. PATENT DOCUMENTS

Examiner's Initials*		Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
LP	AR	5,595,721	01/1997	Kaminski	2	1	
	BR	5,639,600	06/1997	McGrath	1	1	
	CR	5,677,180	10/1997	Robinson	1	1	
	DR	5,716,612	02/1998	Rybak	1	1	
	ER	5,736,137	04/1998	Anderson	1	1	
	FR	5,770,190	06/1998	Bruserud	1	1	
	GR	5,837,293	11/1998	De Waal Malefyt	1	1	
LB	HR	5,871,725	02/1999	Schwarz	1	1	

FOREIGN PATENT DOCUMENTS

		Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract	Translation Readily Available
LB	IR	WO00/20864	04/2000	PCT	Barbera-Guillem		
LB	JR	WO98/56418	12/1998	PCT	Lam		

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

LB	KR	Beatty PR et al., "Involvement of IL-10 in the autonomous growth of EBV-transformed B cell lines," <i>J Immunol</i> , 1997, 158: 4045-4051.					
	LR	Bonavida B et al., "Synergy is documented in vitro with low-dose recombinant tumor necrosis factor, cisplatin, and doxorubicin in ovarian cancer cells," <i>Gynecol Oncol</i> , 1990, 38: 333-339.					
	MR	Cortes J et al., "Interleukin-10 in non-Hodgkin's lymphoma," <i>Leuk Lymphoma</i> , 1997, 26: 251-9.					
	NR	Dedoussis GV et al., "Endogenous interleukin 6 conveys resistance to cis-diamminedichloroplatinum-mediated apoptosis of the K562 human leukemic cell line," <i>Exp Cell Res</i> , 1999, 249: 269-278.					
	OR	Hekman A et al., "Initial experience with treatment of human B cell lymphoma with anti-CD19 monoclonal antibody," <i>Cancer Immunol Immunother</i> , 1991, 32: 364-372.					
	PR	Kiesel S et al., "Removal of cells from a malignant B-cell line from bone marrow with immunomagnetic beads and with complement and immunoglobulin switch variant mediated cytotoxicity," <i>Leuk Res</i> , 1987, 11: 1119-1125.					
	QR	Mosmann TR et al., "Isolation of monoclonal antibodies specific for IL-4, IL-5, IL-6, and a new Th2-specific cytokine (IL-10), cytokine synthesis inhibitory factor, by using a solid phase radioimmunoassay," <i>J Immunol</i> , 1990, 145: 2938-2945.					
	RR	Press OW et al., "Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas," <i>Blood</i> , 1987, 69: 584-591.					
	SR	Stasi R et al., "Clinical implications of cytokine and soluble receptor measurements in patients with newly-diagnosed aggressive non-Hodgkin's lymphoma," <i>Eur J Haematol</i> , 1995, 54: 9-17.					
	TR	Vlasveld LT et al., "Treatment of low-grade non-Hodgkin's lymphoma with continuous infusion of low-dose recombinant interleukin-2 in combination with the B-cell-specific monoclonal antibody CLB-CD19," <i>Cancer Immunol Immunother</i> , 1995, 40: 37-47.					
	UR	Voorzanger N et al., "Interleukin (IL)-10 and IL-6 are produced in vivo by non-Hodgkin's lymphoma cells and act as cooperative growth factors," <i>Cancer Res</i> , 1996, 56: 5499-5505.					
	VR	Wang Z et al., "Sensitization by interleukin-1alpha of carboplatinum anti-tumor activity against human ovarian (NIH:OVCAR-3) carcinoma cells in vitro and in vivo," <i>Int J Cancer</i> , 1996, 68: 583-587.					
LB	WR	Yonish-Rouach E et al., "Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6," <i>Nature</i> , 1991, 352: 345-347.					

LR	XR	<i>Idec Pharmaceuticals and Corixa Corp.</i> , Case No. 01-1637-IEG [Doc. Nos. 486, 584] (S.D. Cal. Oct. 14, 2003).
LR	YR	<i>Biogen Idec v. Corixa Corp.</i> , Case No. 01-1637-IEG [Doc. Nos. 635, 662, 486] (S.D. Cal. Jan. 22, 2004).
Examiner		Date Considered: 12/10/04
<p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.</p>		

JUN 01 2004



FORM PTO-1449 (modified)
To: U.S. Department of Commerce
(PW FORM PAT-1449)
Patent and Trademark Office



Atty. Dkt. No.	M#	Client Ref.
	0280062	2000-30-0178A

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Applicant: NABIL HANNA	
Appln. No.: 09/822,672	
Filing Date: April 2, 2001	
Examiner: Larry R. Helms	Group Art Unit: 1642

Date: October 8, 2003 Pa
ge 1 of 1

U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
JDA	AR 6,455,043	09/2002	GRILLO-LOPEZ	✓	✓	
	BR					
	CR					
	DR					
	ER					
	FR					

FOREIGN PATENT DOCUMENTS

		Document Number	Date MM/YYYY	Country	Inventor Name		Abstract		Readily Available	
							Enclosed	No	Enclose	No
	GR									
	HR									
	IR									
	JR									
	KR									
	LR									


OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

MR							
NR							
OR							
PR							
QR							
RR							
SR							
TR							
UR							
VR							
WR							
XR							
YR							
ZR							
AAR							
BBR							
CCR							

Examiner Date Considered:

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 (modified)
T : U.S. Department of Commerce
(PW FORM PAT-1449)
Patent and Trademark Office



Atty.
Dkt. No.

M#

Client Ref.

0280062

2000-30-0178A

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Applicant: NABIL HANNA

Appln. No.: 09/822,672

Filing Date: April 2, 2001

Examiner: Larry R. Helms

Group Art Unit: 1642

Date: October 8, 2003

Page

1

of

1

U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
	AR	6,455,043	09/2002	GRILLO-LOPEZ		
	BR					
	CR					
	DR					
	ER					
	FR					

FOREIGN PATENT DOCUMENTS

		Document Number	Date MM/YYYY	Country	Inventor Name		Abstract		Readily Available	
							Enclosed	No	Enclose	No
	GR									
	HR									
	IR									
	JR									
	KR									
	LR									

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

	MR						
	NR						
	OR						
	PR						
	QR						
	RR						
	SR						
	TR						
	UR						
	VR						
	WR						
	XR						
	YR						
	ZR						
	AAR						
	BBR						
	CCR						

Examiner


Date Considered:

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 (modified)
To: U.S. Department of Commerce
(PW FORM PAT-1449)
Patent and Trademark Office

Atty. Dkt. No.	M#	Client Ref.
	0280062	2000-30-0178A

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**



Applicant: HANNA.

Appln. No.: 09/822,672

Filing Date: April 2, 2001

Examiner: Larry Helms

Group Art Unit: 1642

Date: December 24, 2003 Page 1 of 1

U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date
LR	AR 6,183,744 B1	02/2001	Goldenberg	✓		
LR	BR 6,306,393 B1	10/2001	Goldenberg	✓		
	CR					
	DR					
	ER					
	FR					

RECEIVED

DEC 31 2003

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract	Translation Readily Available
GR					
HR					
IR					
JR					
KR					
LR					

OTHER

LR	MR	Kaminski, et al., "Radioimmunotherapy of Advanced B-Cell Lymphoma with Non Bone Marrow Ablative Doses of 131-I MB-1 Antibody," 1990, <i>Antibody Immunoconjugates, and Radiopharmaceuticals</i> , Vol. 3, No. 1, Abstract No. 83.
	NR	Kaminski, et al., "Radioimmunodetection (RID) and Non Marrow Ablative Radioimmunotherapy (RIT) of B-Cell Lymphoma With 131-I MB-1 Antibody," 1990, <i>Proceedings of ASCO</i> , Vol. 9, p. 271, Abstract No. 1051.
	OR	Wahl, et al., "Radioimmunotherapy of B-Cell Lymphoma with 131 MB-1 Monoclonal Antibody," <i>The Journal of Nuclear Medicine: Proceedings of the 37th Annual Meeting</i> , p. 852, Abstract No. 622.
	PR	Kaminski, et al., "Phase I Trial Results of 131-I MB-1 Antibody Radioimmunotherapy (RAIT) of B-Cell Lymphoma," 1990, <i>Antibody Immunoconjugates, and Radiopharmaceuticals</i> , Vol. 4, No. 1, p. 36, Abstract No. 66.
	QR	Kaminski, et al., "Phase I Evaluation of 131-I MB-1 Antibody Radioimmunotherapy (RIT) of B-Cell Lymphoma," 1990, <i>Blood</i> , Vol. 76, No. 10, p. 355a, Abstract No. 1409.
LR	RR	Kaminski, et al., "Imaging, Dosimetry, and Radioimmunotherapy With Iodine 131-Labeled Anti-CD37 Antibody in B-Cell Lymphoma," 1992, <i>Journal of Clinical Oncology</i> , Vol. 10, No. 11, pp. 1696-1711.
LR	SR	Jensen, et al., "Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC C2B8, rituximab)," 1998, <i>Ann Hematol</i> , Vol. 77, pp. 89-91.
	TR	

Examiner

Date Considered:

12/15/04

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.